Treatment of age-related macular degeneration: focus on ranibizumab
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A, significantly slows down loss of vision and causes...
Saved in:
Main Authors: | Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter Szurman |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/808111db7fc941a4b85f538425fd4db2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
by: Dervenis N, et al.
Published: (2016) -
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
by: Tryfon Rotsos, et al.
Published: (2010) -
Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
by: Otsuji T, et al.
Published: (2013) -
Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication
by: Damasceno N, et al.
Published: (2012) -
The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
by: Gungel H, et al.
Published: (2014)